NASDAQ · XBIO
Healthcare · Biotechnology
$2.12
Up+$0.01 (+0.47%)
Updated Oct 10, 2026, 1:33 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · XBIO
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
XBIO closed at $2.12 after 20 trading sessions, down 45.64% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $2.18 | $2.18 | $2.10 | $2.12 | 13.55K |
| Oct 7, 2026 | $2.11 | $2.21 | $2.11 | $2.21 | 15.56K |
| Oct 6, 2026 | $2.19 | $2.3405 | $2.1001 | $2.12 | 14.73K |
| Oct 5, 2026 | $2.23 | $2.29 | $2.19 | $2.20 | 9.53K |
| Oct 2, 2026 | $2.30 | $2.33 | $2.1103 | $2.24 | 43.3K |
| Oct 1, 2026 | $2.335 | $2.335 | $2.21 | $2.24 | 13.38K |
| Sep 30, 2026 | $2.26 | $2.3348 | $2.22 | $2.32 | 33.48K |
| Sep 29, 2026 | $2.34 | $2.35 | $2.25 | $2.26 | 12.35K |
| Sep 28, 2026 | $2.37 | $2.475 | $2.23 | $2.33 | 34.8K |
| Sep 25, 2026 | $2.42 | $2.5304 | $2.3302 | $2.39 | 50.72K |
| Sep 24, 2026 | $2.56 | $2.56 | $2.28 | $2.47 | 64.03K |
| Sep 23, 2026 | $2.65 | $2.65 | $2.43 | $2.52 | 91.4K |
| Sep 22, 2026 | $2.99 | $2.99 | $2.4359 | $2.57 | 155.12K |
| Sep 21, 2026 | $2.81 | $3.10 | $2.80 | $2.99 | 145.78K |
| Sep 18, 2026 | $2.50 | $2.80 | $2.30 | $2.77 | 415K |
| Sep 17, 2026 | $2.27 | $2.46 | $2.15 | $2.46 | 672.88K |
| Sep 16, 2026 | $2.75 | $2.7888 | $1.87 | $2.19 | 1.51M |
| Sep 15, 2026 | $4.33 | $4.33 | $4.0882 | $4.27 | 5.88K |
| Sep 14, 2026 | $4.00 | $4.33 | $3.8522 | $4.33 | 66.84K |
| Sep 11, 2026 | $4.07 | $4.11 | $3.8367 | $3.90 | 37.65K |
The latest Smart Investors Daily articles mentioning XBIO.
Company
Market Activity
Research & News
XBIO research
Company profile and research snapshot.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 9, 2025 | HC Wainwright & Co. | Neutral | — |
| Mar 20, 2025 | HC Wainwright & Co. | Neutral | — |
| Dec 5, 2024 | HC Wainwright & Co. | Neutral | — |
| Nov 22, 2024 | HC Wainwright & Co. | Neutral | — |
| Aug 20, 2024 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
Benzinga · Sep 22, 2026
Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved upwards by
Yahoo · Sep 16, 2026
The proposed transaction would create a Nasdaq-listed company focused on NET-targeting therapies, combining four clinical programs while transferring majority ownership to Santersus shareholders. Key Investor TakeawaysXenetic Biosciences (NASDAQ:XBIO) has signed a definitive share exchange agreement to acquire privately held Santersus AG in an all-stock transaction.
Yahoo · Sep 16, 2026
Xenetic Biosciences Inc. (NASDAQ:XBIO) on Wednesday struck a definitive share exchange agreement to purchase Santersus AG, a privately held therapeutic medical device firm advancing its selective blood purification platform. The all-stock deal hinges on shareholder approval and involves exchanging newly issued Xenetic shares for all outstanding Santersus equity. Following the transaction, the unified entity plans to rebrand as Santersus Bio, Inc. and trade on the Nasdaq Capital Market under the
SeekingAlpha · Sep 16, 2026
Xenetic Biosciences, Inc. (XBIO) M&A Call September 16, 2026 8:30 AM EDTCompany ParticipantsJames Parslow - CFO, COO, Interim CEO & Corporate...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XBIO.
